Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 1001-1006, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-920981
ABSTRACT
Human epidermal growth factor receptor 2 (HER-2) plays an important role in carcinogenesis and development of urothelial carcinoma. Overexpression of HER-2 is associated with poor prognosis of urothelial carcinoma. Although there is no significant benefit from anti-HER-2 targeted therapies of monoclonal antibody and tyrosine kinase inhibitor, Anti-HER-2 antibody-drug conjugate (HER-2-ADC) has shown a promising efficacy in urothelial carcinoma patients with HER-2 overexpression. Therefore, effectively screening the potential beneficiaries of HER-2-ADC drugs has become a new challenge. However, standardized HER-2 scoring system for urothelial carcinoma has yet to be developed. Thus, the Committees organized experts to reach this expert consensus based on the clinical practice of HER-2 expression, gene amplification and mutation testing in urothelial carcinoma, combined with the current research progress and internal discussion of committee members, in order to construct HER-2 testing standard of urothelial carcinoma and improve the accuracy of interpretation, to guide the clinical application.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Receptor, ErbB-2
/
Consensus
Type of study:
Practice guideline
/
Prognostic study
/
Qualitative research
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS